Up-and-Coming Chinese Biotech BeiGene Gets $750M Worth of Love From U.S. Investors
The company will use the cash for working capital and general corporate purposes, including R&D activities.
Source: BioSpace
The company will use the cash for working capital and general corporate purposes, including R&D activities.
Source: BioSpace